Characteristics of predominantly STEMI studies
| Study | Patients (n) | PCI (%) | Bivalirudin (n) | UFH (n) | Bivalirudin design | UFH design | Female (%) | Mean age (year) | Follow-up (days) | GPI use (%) | Transradial (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bivalirudin | UFH | |||||||||||
| HORIZONS-AMI, 200813 | 3602 | 93 | 1800 | 1802 | Intravenous bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h | Intravenous bolus of 60 U/kg with subsequent boluses targeted to ACT of 200–250 s | 23 | 60 | 30 | 8 | 98 | 6 |
| EUROMAX, 20135 | 2218 | 86 | 1089 | 1109 | Intravenous bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h | Intravenous bolus of 100 U/kg without GPI or 60 U/kg with GPI | 24 | 62 | 30 | 12 | 69 | 47 |
| Heat-PPCI, 201410 | 1812 | 82 | 905 | 907 | Intravenous bolus of 0·75 mg/kg followed by infusion of 1·75 mg/kg/h. A rebolus of 0·3 mg/kg was administered if ACT values were <225 s | Intravenous bolus of 70 U/kg with subsequent boluses if ACT values were <200 s | 28 | 63 | 28 | 13 | 15 | 81 |
| BRIGHT*, 201517 | 2178 | 97 | 729 | 1449 | Intravenous bolus of 0.75 mg/kg, followed by a continuous infusion of 1.75 mg/kg/h If ACT was <225 s, an additional bolus of 0.3 mg/kg was added | Intravenous bolus of 100 U/kg without GPI or 60 U/kg with GPI, with subsequent boluses if ACT values were <200 s | 18 | 58 | 30 | 4 | 53 | 79 |
| BRAVE 4, 201411 | 548 | 92 | 271 | 277 | Intravenous bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h | Intravenous bolus of 70–100 U/kg with subsequent boluses according to ACT | 23 | 61 | 30 | 3 | 6 | <1 |
*The trial involved three arms: bivalirudin alone, UFH alone, and UFH plus GPI.
ACT, activated clotting time; GPI, glycoprotein IIb/IIIa inhibitors; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction; UFH, unfractionated heparin.